RR

1,192

+2.94%↑

BATS

4,262

-0.88%↓

BAE

2,146

-4.15%↓

REL

2,465

-2.1%↓

AAL

3,017

+4.58%↑

RR

1,192

+2.94%↑

BATS

4,262

-0.88%↓

BAE

2,146

-4.15%↓

REL

2,465

-2.1%↓

AAL

3,017

+4.58%↑

RR

1,192

+2.94%↑

BATS

4,262

-0.88%↓

BAE

2,146

-4.15%↓

REL

2,465

-2.1%↓

AAL

3,017

+4.58%↑

RR

1,192

+2.94%↑

BATS

4,262

-0.88%↓

BAE

2,146

-4.15%↓

REL

2,465

-2.1%↓

AAL

3,017

+4.58%↑

RR

1,192

+2.94%↑

BATS

4,262

-0.88%↓

BAE

2,146

-4.15%↓

REL

2,465

-2.1%↓

AAL

3,017

+4.58%↑

Search

Halma PLC

Закрыт

СекторПромышленность

3,730 2.81

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

3516

Макс.

3792

Ключевые показатели

By Trading Economics

Доход

107M

187M

Продажи

651M

1.2B

P/E

Средняя по отрасли

41.717

61.065

Прибыль на акцию

0.553

Дивидендная доходность

0.61

Рентабельность продаж

15.096

Сотрудники

9,000

EBITDA

184M

317M

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+9.76% upside

Дивиденды

By Dow Jones

Дивидендная доходность

Средняя по отрасли

0.61%

2.23%

Следующий отчет о доходах

11 июн. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

703M

14B

Предыдущая цена открытия

3727.19

Предыдущая цена закрытия

3730

Halma PLC График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

23 мар. 2026 г., 23:47 UTC

Приобретения, слияния, поглощения

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

23 мар. 2026 г., 22:55 UTC

Приобретения, слияния, поглощения

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

23 мар. 2026 г., 21:51 UTC

Приобретения, слияния, поглощения

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

23 мар. 2026 г., 23:59 UTC

Обсуждения рынка

Global Equities Roundup: Market Talk

23 мар. 2026 г., 23:59 UTC

Обсуждения рынка

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

23 мар. 2026 г., 23:50 UTC

Обсуждения рынка

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

23 мар. 2026 г., 23:37 UTC

Обсуждения рынка

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

23 мар. 2026 г., 22:42 UTC

Обсуждения рынка
Главные новостные события

Global Equities Roundup: Market Talk

23 мар. 2026 г., 22:42 UTC

Обсуждения рынка
Главные новостные события

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

23 мар. 2026 г., 22:40 UTC

Приобретения, слияния, поглощения

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

23 мар. 2026 г., 22:23 UTC

Обсуждения рынка

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

23 мар. 2026 г., 22:22 UTC

Приобретения, слияния, поглощения

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

23 мар. 2026 г., 22:21 UTC

Приобретения, слияния, поглощения

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

23 мар. 2026 г., 22:21 UTC

Приобретения, слияния, поглощения

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

23 мар. 2026 г., 22:20 UTC

Приобретения, слияния, поглощения

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

23 мар. 2026 г., 22:20 UTC

Приобретения, слияния, поглощения

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

23 мар. 2026 г., 22:19 UTC

Приобретения, слияния, поглощения

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

23 мар. 2026 г., 22:19 UTC

Приобретения, слияния, поглощения

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

23 мар. 2026 г., 22:18 UTC

Приобретения, слияния, поглощения

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

23 мар. 2026 г., 22:15 UTC

Приобретения, слияния, поглощения

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

23 мар. 2026 г., 22:08 UTC

Обсуждения рынка

Ebos Needs to Reset Its Gearing Targets -- Market Talk

23 мар. 2026 г., 21:42 UTC

Обсуждения рынка

Global Forex and Fixed Income Roundup: Market Talk

23 мар. 2026 г., 21:42 UTC

Обсуждения рынка

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

23 мар. 2026 г., 21:32 UTC

Отчет

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

23 мар. 2026 г., 21:32 UTC

Отчет

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

23 мар. 2026 г., 21:32 UTC

Отчет

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

23 мар. 2026 г., 21:10 UTC

Главные новостные события

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

23 мар. 2026 г., 20:50 UTC

Обсуждения рынка

Tech, Media & Telecom Roundup: Market Talk

23 мар. 2026 г., 20:50 UTC

Обсуждения рынка

Health Care Roundup: Market Talk

23 мар. 2026 г., 20:50 UTC

Обсуждения рынка
Отчет
Главные новостные события

Basic Materials Roundup: Market Talk

Сравнение c конкурентами

Изменение цены

Halma PLC Прогноз

Целевая цена

By TipRanks

9.76% рост

Прогноз на 12 месяцев

Средняя 3,971.25 GBX  9.76%

Максимум 4,280 GBX

Минимум 3,050 GBX

Основано на мнении 8 аналитиков Wall Street, спрогнозировавших целевые цены для Halma PLC на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

8 ratings

4

Покупка

3

Удержание

1

Продажа

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Halma PLC

Halma plc, together its subsidiaries, provides technology solutions in the safety, health, and environmental markets in the United States, Mainland Europe, the United Kingdom, the Asia Pacific, Africa, the Middle East, and internationally. It operates through three segments: Safety, Environmental & Analysis, and Healthcare. The Safety segment provides products that protect people, assets and infrastructure, and electrical systems which is used in public and commercial spaces and in industrial and logistics operations. This segment serves Fire Safety, Power Safety, Industrial Safety, and Urban Safety markets. The Environmental & Analysis segment offers optical, optoelectronic, and spectral imaging systems; environmental monitoring; analysis of air quality, gases, and water; detection of hazardous gases; and water analysis & treatment systems. It serves the optical analysis, water analysis and treatment, and environmental monitoring markets. The Healthcare segment provides components, devices and systems that provide information and analytics to understand patient health and make decisions across the continuum of care; technologies and solutions to enable in-vitro diagnostic systems and life-science discoveries and development; and technologies that enable treatment across clinical specialties, as well as critical fluidic components used by medical diagnostics and original equipment manufacturers. This segment serves the life sciences, health assessment and analytics, and therapeutic solutions market. The company was incorporated in 1894 and is headquartered in Amersham, the United Kingdom.
help-icon Live chat